Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Reduction of Capital

10 Aug 2023 13:58

RNS Number : 9804I
Dowlais Group PLC
10 August 2023
 

10 August 2023

 

DOWLAIS GROUP PLC

 

Reduction of Capital

 

Dowlais Group plc (the "Company") is pleased to announce that, following formal approval by the High Court of Justice (the "Court") of the cancellation of the entire amount standing to the credit of the Company's share premium account (the "Capital Reduction") on 1 August 2023, the order of the Court confirming the Capital Reduction and statement of capital approved by the Court were registered with the Registrar of Companies on 10 August 2023 and the Capital Reduction has become effective. 

 

Details of the Capital Reduction, the purpose of which was to create distributable reserves, were set out in the prospectus published by the Company on 3 March 2023 for the admission of the issued share capital of the Company to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange plc's main market for listed securities, and the Capital Reduction was approved by shareholders at a general meeting of the Company on 28 February 2023.

 

Following the Capital Reduction, the issued share capital of the Company has not changed and consists of 1,393,273,527 ordinary shares of £0.01 each.

 

 

 

Enquiries:

 

John Nicholson

General Counsel and Company Secretary

+44 (0)204 551 33833

LEI Number: 213800XM8WOFLY6VPC92

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZGMRZGVGFZM

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.